Radiopharm advances oncology pipeline as cash reserves hit $34.5M
Clinical-stage biopharmaceutical leader Radiopharm Theranostics (ASX:RAD) has released its financial results for the first half of fiscal 2026, reporting a cash position of $34.5 million and a series of significant clinical breakthroughs.


-640x360.jpg&w=3840&q=75)








